Akero Therapeutics, Inc. (NASDAQ:AKRO) Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC trimmed its holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO) by 7.9% during the third quarter, Holdings Channel.com reports. The fund owned 60,416 shares of the company’s stock after selling 5,198 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Akero Therapeutics were worth $1,733,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in AKRO. Mirae Asset Global Investments Co. Ltd. grew its stake in Akero Therapeutics by 21.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,511 shares of the company’s stock valued at $71,000 after acquiring an additional 446 shares during the last quarter. Eastern Bank acquired a new stake in Akero Therapeutics in the 3rd quarter valued at about $100,000. Summit Financial Wealth Advisors LLC acquired a new stake in shares of Akero Therapeutics during the 3rd quarter worth about $205,000. Victory Capital Management Inc. acquired a new stake in shares of Akero Therapeutics during the 3rd quarter worth about $211,000. Finally, Quest Partners LLC boosted its stake in shares of Akero Therapeutics by 22,021.1% during the 2nd quarter. Quest Partners LLC now owns 12,609 shares of the company’s stock worth $296,000 after purchasing an additional 12,552 shares during the last quarter.

Insider Transactions at Akero Therapeutics

In related news, VP Patrick Lamy sold 925 shares of the firm’s stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $30.79, for a total value of $28,480.75. Following the transaction, the vice president now owns 17,858 shares in the company, valued at approximately $549,847.82. This trade represents a 4.92 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Andrew Cheng sold 24,992 shares of the firm’s stock in a transaction that occurred on Wednesday, October 16th. The shares were sold at an average price of $31.14, for a total transaction of $778,250.88. Following the completion of the transaction, the chief executive officer now owns 605,417 shares in the company, valued at $18,852,685.38. The trade was a 3.96 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 396,099 shares of company stock worth $12,361,885 in the last three months. Company insiders own 7.94% of the company’s stock.

Akero Therapeutics Trading Up 1.2 %

Shares of AKRO stock opened at $29.23 on Tuesday. The firm has a market cap of $2.04 billion, a P/E ratio of -7.79 and a beta of -0.23. Akero Therapeutics, Inc. has a 1-year low of $15.32 and a 1-year high of $37.00. The company has a debt-to-equity ratio of 0.05, a current ratio of 17.25 and a quick ratio of 17.25. The firm’s 50-day simple moving average is $30.86 and its 200-day simple moving average is $27.27.

Akero Therapeutics (NASDAQ:AKRO) last announced its quarterly earnings data on Friday, November 8th. The company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($0.90) by ($0.15). As a group, equities analysts forecast that Akero Therapeutics, Inc. will post -3.96 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on AKRO shares. HC Wainwright reaffirmed a “buy” rating and set a $50.00 price target on shares of Akero Therapeutics in a research note on Monday, November 18th. Citigroup started coverage on shares of Akero Therapeutics in a research note on Monday, November 18th. They set a “buy” rating and a $65.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $46.83.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.